Related references
Note: Only part of the references are listed.The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
Jens U. Marquardt et al.
TARGETED ONCOLOGY (2019)
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Masatoshi Kudo
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
miR-34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE-A/p53 signaling
Ge Yang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism
Hai-Feng Zhang et al.
MOLECULAR MEDICINE REPORTS (2018)
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
Stefania Gorini et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Crosstalk in cancer resistance and metastasis
Saeed Norouzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1
Meryem Guelfem Oener et al.
GASTROENTEROLOGY (2018)
Structural and functional aspects of P-glycoprotein and its inhibitors
Shirin Mollazadeh et al.
LIFE SCIENCES (2018)
MiRNA 34a: a therapeutic target for castration-resistant prostate cancer
Marine J. Chalanqui et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis
Dimiter B. Avtanski et al.
MOLECULAR ONCOLOGY (2016)
Plasmatic microRNA as Potential Biomarkers of Multiple Sclerosis: Literature Review
Magdalena J. Kacperska et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
Mihalis S. Kariolis et al.
NATURE CHEMICAL BIOLOGY (2014)
Mir-34a Mimics Are Potential Therapeutic Agents for p53-Mutated and Chemo-Resistant Brain Tumour Cells
Yuen Ngan Fan et al.
PLOS ONE (2014)
microRNA-34a Sensitizes Lung Cancer Cell Lines to DDP Treatment Independent of p53 Status
Xi Wang et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Gyoergy Baffy et al.
JOURNAL OF HEPATOLOGY (2012)
Effects of Quercetin on the Bioavailability of Doxorubicin in Rats: Role of CYP3A4 and P-gp Inhibition by Quercetin
Jun-Shik Choi et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review)
May Y. W. Wong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
MicroRNA regulation by RNA-binding proteins and its implications for cancer
Marieke van Kouwenhove et al.
NATURE REVIEWS CANCER (2011)
The miR-34 family in cancer and apoptosis
H. Hermeking
CELL DEATH AND DIFFERENTIATION (2010)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Hepatocellular Carcinoma: Current Management
Charles H. Cha et al.
CURRENT PROBLEMS IN SURGERY (2010)
MiR-34, SIRT1 and p53 The feedback loop
Munekazu Yamakuchi et al.
CELL CYCLE (2009)
Liver Tumor Ablation: Percutaneous and Open Approaches
Srikanth Padma et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
p53 and E2f: partners in life and death
Shirley Polager et al.
NATURE REVIEWS CANCER (2009)
Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment
Ricardo Perez-Tomas
CURRENT MEDICINAL CHEMISTRY (2006)
Share Paper
